Synergism Between Sequential Immunotherapy and Radiotherapy in A Malignant Pleural Mesothelioma Patient

Criel M^*, Vandermeulen A, Vanhove K, Van De Kerkhove C, Nackaerts K, Lambrecht M and Berkovic P

Department of Respiratory Oncology, University Hospitals Leuven, Belgium

*Corresponding Author : Martein Criel, Department of Respiratory Oncology
University Hospitals Leuven, Belgium
E-mail: maarten.criel@uzleuven.be

Received: May 20, 2020 Accepted: September 18, 2020 Published: September 26, 2020

Citation: Criel M, Vandermeulen A, Vanhove K, Van De Kerkhove C, Nackaerts K, et al. (2020) Synergism Between Sequential Immunotherapy and Radiotherapy in a Malignant Pleural Mesothelioma Patient. Clin Oncol Case Rep 3:5. DOI: 10.37532/cocr.2020.3(5).143

Malignant Pleural Mesothelioma (MPM) is a highly invasive tumor that is linked to previous asbestos exposure. Combined multimodality treatment, i.e induction chemotherapy followed by surgery, is standard of care in highly selected patients. Platinum-doublet chemotherapy is the first choice for inoperable or advanced disease. There are no good recommendations for second-line treatment due to the lack of a clear survival benefit. Chest wall invasion is common and radiotherapy is used for pain control. We report the case of an MPM patient that showed a remarkable response through the combination of radiotherapy and immunotherapy. This case illustrates that despite failure of single-agent checkpoint inhibition, the combination of radiotherapy and immunotherapy has the potential to overcome checkpoint-inhibitor resistance in MPM.